MAAT PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.06 EUR | 0.00% |
|
+3.90% | +29.80% |
Presenter SpeechHerve Affagard (Executives)Good evening. I'm Herve Affagard. I'm the Co-Founde...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors.
The company has a portfolio of 2 products in clinical development, including 1 in Phase III (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase IIb (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.06
EUR
Average target price
15.5
EUR
Spread / Average Target
+71.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.80% | 112M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MAAT Stock
- News MaaT Pharma
- Transcript : MaaT Pharma SA - Special Call
